All In Biotech

Drug Trial Radar · NCT01215227

An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)

A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)

Last checked: Nov 20, 2026Latest source record: Nov 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 839 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

839

Actual

Start

Nov 18, 2010

Primary completion

Jul 16, 2013

Study completion Jul 16, 2013

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 6, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 30 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this extension study is to assess the long-term safety and tolerability of preladenant in participants from parent studies NCT01155466 \[P04938\] and NCT01227265 \[P07037\] with moderate to severe Parkinson's Disease (PD). The study will also characterize the long-term efficacy of preladenant in participants with PD. Participants will continue to receive their stable regimen of levodopa (L-dopa) plus any adjunct medications during the study as prescribed by their physician. Several classes of adjunct medications may be used, including Amantadine, anticholinergics, dopa decarboxylase inhibitors, and dopamine agonists.

Conditions

  • Parkinson Disease
  • Idiopathic Parkinson Disease

Interventions

  • PreladenantDrug

    Daily for 40 weeks: 2, 5, or 10 mg preladenant tablet each morning; 2, 5, or 10 mg preladenant tablet each evening (approximately 8 hours after the morning dose)

  • RasagilineDrug

    Daily for 40 weeks: 1 mg rasagiline capsule each morning

  • Placebo to preladenantDrug

    Placebo to match preladenant given daily for 40 weeks: placebo tablet each morning; placebo tablet each evening (approximately 8 hours after the morning dose)

  • Placebo to rasagilineDrug

    Placebo to match rasagiline given daily for 40 weeks: placebo capsule each morning

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Systolic Blood Pressure ≥180 mmHgTime frame: Up to 42 weeks
  2. Percentage of Participants With Diastolic Blood Pressure ≥105 mmHgTime frame: Up to 42 weeks
  3. Percentage of Participants With Alanine Aminotransferase (ALT) ≥3 Times Upper Limit of Normal and ≥10% Increase From BaselineTime frame: Up to 42 weeks
  4. Percentage of Participants With Aspartate Aminotransferase (AST) ≥3 Times Upper Limit of Normal and ≥10% Increase From BaselineTime frame: Up to 42 weeks
  5. Percentage of Participants With SuicidalityTime frame: Up to 42 weeks
  6. Percentage Change From Baseline in Total Epworth Sleepiness Scale (ESS) Score at Week 40Time frame: Baseline and Week 40

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.